Novavax (NVAX)
(Delayed Data from NSDQ)
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
by Sundeep Ganoria
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
by Zacks Equity Research
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
Novavax (NVAX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -45.60% and 8.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Novavax (NVAX) settling at $12.57, representing a -1.87% change from its previous close.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 15.15% and 5.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Novavax (NVAX) have performed compared to their sector so far this year.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Wall Street Bulls Look Optimistic About Novavax (NVAX): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Novavax (NVAX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Novavax (NVAX) closed at $12.06, indicating a +1.34% shift from the previous trading day.
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
by Zacks Equity Research
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
by Zacks Equity Research
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.